

## **NMS Labs**

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208 Phone: (215) 657-4900 Fax: (215) 657-2972 e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

**Demo Report** 

**Report Issued** 03/30/2020 12:01 **Last Report Issued** 03/09/2009 14:47

88888

Clinical Example Report Attn: Example Reports 200 Welsh Road Horsham, PA 19044 Patient Name 1491SP-POS Patient ID 1491SP-POS

**Chain** 09001502

Age Not Given DOB Not Given

**Gender** Not Given

**Workorder** 09001502

**Received** 03/09/2009 14:45

Sample ID 09001502-001 Matrix Serum or Plasma Patient Name 1491SP-POS Patient ID 1491SP-POS Container Type Clear vial Collect Dt/Tm Not Given Source Not Given

Approx Vol/Weight Not Given

Receipt Notes None Entered

Analysis and Comments	Result	Units	Reporting Limit	Notes
1491SP Desvenlafaxine, Serum/Plasma				
Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS)				
Desvenlafaxine	5000	ng/mL	10	
Synonym(s): Pristiq®; O-Desmethylvenlafaxine				
Mean peak plasma concentrations +/- S.D., obtained at approximately 7.5 hours after dosing, were reported as follows: 75 mg (sustained release) oral dose: 135 +/- 54 ng/mL 100 mg (sustained release) oral dose: 238 +/- 45 ng/mL 150 mg (sustained release) oral dose: 284 +/- 83 ng/mL				

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.

Page 1 of 1 NMS v.40.0